Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes

Journal of Clinical Virology

Volumn 54, Issue 1, 2012, Pages 21-25

  Aitken, Susan C ^a,b   Kliphuis, Aletta ^a,c   Wallis, Carole L ^b   Chu, Mei Ling ^a   Fillekes, Quirine ^d   Barth, Roos ^a   Stevens, Wendy ^b,e   Rinke de Wit, Tobias F ^c,f   Schuurman, Rob ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c PharmAccess International   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^f AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

Drug resistance; Genotyping; Group m subtypes; HIV 1

Indexed keywords

AMINO ACID; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; VALIDATION PROCESS; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AFRICA; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84861911931     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.01.010     Document Type: Article

References (26)

1. UNAIDS Report on the global AIDS epidemic http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.
2. Temesgen Z., Warnke D., Kasten M.J. Current status of antiretroviral therapy. Exp Opin Pharmacother 2006, 7(August (12)):1541-1554.
3. Hamers R.L., Wallis C.L., Kityo C., Siwale M., Mandaliya K., Conradie F., et al. HIV-1 drug resistance among antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: multicentre observational study. Lancet Infect Dis 2011, 11. Published online July 28, 70149-9. 10.1016/s1473-3099.
4. Tang J.W., Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004, 30(May (1)):1-10.
5. Barth R.E., Aitken S.C., Templeman H., Geelen S.P., van Bussel E.M., Hoepelman A.I.M., et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subytpe-C-infected patients. Antivir Ther 2011, Accepted for publication 2011. 10.3851/IMP2010.
6. Muro E.P., Fillekes Q., Kisanga E., L'homme R., Aitken S.C., Mariki G., et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. J Acquir Immune Defic Syndr 2012, Epud ahead of print, 10.1097/QAI.0b013e31824234d8.
7. Huigen M.C., de Graaf L., Eggink D., Schuurman R., Muller V., Stamp A., et al. Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology 2007 Aug 1, 364(2):395-406.
8. Nijhuis M., Boucher C.A., Schipper P., Leitner T., Schuurman R., Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998, 95(November (24)):14441-14446.
9. Nijhuis M., Boucher C.A., Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 1995, 19(August (2)):178-180. 182.
10. Wallis C.L., Papathanasopoulos M.A., Lakhi S., Karita E., Kamali A., Kaleebu P., et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010, 163(February (2)):505-508.
11. Aghokeng A.F., Mpoudi-Ngole E., Chia J.E., Edoul E.M., Delaporte E., Peeters M. High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J Clin Microbiol 2011, 49(April (4)):1635-1641.
12. Buckton A.J., Bissett S.L., Myers R.E., Beddows S., Edwards S., Cane P.A., et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother 2008, 62(December (6)):1191-1198.
13. Plantier J.C., Dachraoui R., Lemee V., Gueudin M., Borsa-Lebas F., Caron F., et al. HIV-1 resistance genotyping on dried serum spots. Aids 2005, 19(March (4)):391-397.
14. Steegen K., Demecheleer E., De Cabooter N., Nges D., Temmerman M., Ndumbe P., et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods 2006, 133(May (2)):137-145.
15. McNulty A., Jennings C., Bennett D., Fitzgibbon J., Bremer J.W., Ussery M., et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 2007, 45(February (2)):517-521.
16. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005, 192(September (6)):958-966.
17. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of health and human services. December 1, 2009 (cited November 12, 2010). Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
18. Bennett D.E., Bertagnolio S., Sutherland D., Gilks C.F. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008, 13(Suppl. 2):1-13.
19. Ayele W., Schuurman R., Messele T., Dorigo-Zetsma W., Mengistu Y., Goudsmit J., et al. Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden. J Clin Microbiol 2007, 45(March (3)):891-896.
20. Bertagnolio S., Soto-Ramirez L., Pilon R., Rodriguez R., Viveros M., Fuentes L., et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007, 12(1):107-113.
21. Dachraoui R., Brand D., Brunet S., Barin F., Plantier J.C. RNA amplification of the HIV-1 Pol and env regions on dried serum and plasma spots. HIV Med 2008, 9(August (7)):557-561.
22. Hallack R., Doherty L.E., Wethers J.A., Parker M.M. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008, 41(April (4)):283-287.
23. Marconi A., Balestrieri M., Comastri G., Pulvirenti F.R., Gennari W., Tagliazucchi S., et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 2009, 15(January (1)):93-97.
24. Masciotra S., Garrido C., Youngpairoj A.S., McNulty A., Zahonero N., Corral A., et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. Aids 2007, 21(November (18)):2503-2511.
25. Aitken S.C., Tempelman H., Schrooders P., Slabbert M., Schuurman R., Wensing A.M. Resistance testing on dried blood spots enables individual patient management in rural South African settings. Global Antivir J 2010, 6(Suppl. 1):65.
26. WHO WHO/HIVResNet HIV drug resistance: laboratory strategy http://www.who.int/hiv/pub/drugresistance/hiv_reslab_strategy.pdf.